Janssen combats Harvoni competition with UK Olysio 'pay if you clear' scheme

Janssen has offered England and Scotland the chance to prescribe hepatitis C drug Olysio (simeprevir) on the National Health Service, and only pay for it in those patients who clear the virus within 12 weeks. Janssen's timing coincides with growing competition in the HCV space, and may be a way of fending off rivalry from Gilead's Harvoni (sofosbuvir and ledipasvir).